XML 55 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information (Tables)
6 Months Ended
Dec. 31, 2018
Segment Reporting [Abstract]  
Net Revenue and Segment EBITDA The following tables include net revenue and Segment EBITDA during the three and six months ended December 31, 2018 and 2017:
Three Months Ended  
December 31,
Six Months Ended  
December 31,
(Dollars in millions)2018201720182017
Softgel Technologies
Net revenue$213.7 $228.1 $412.9 $447.8 
Segment EBITDA$44.2 $50.1 $77.5 $85.2 
Biologics and Specialty Drug Delivery
Net revenue184.3 148.7 338.9 240.4 
Segment EBITDA50.8 39.9 77.3 48.6 
Oral Drug Delivery
Net revenue154.0 137.2 284.1 271.8 
Segment EBITDA44.8 41.2 72.2 79.9 
Clinical Supply Services
Net revenue80.8 108.7 158.5 218.4 
Segment EBITDA21.0 19.0 41.2 35.7 
Inter-segment revenue elimination(9.8)(16.4)(19.6)(28.2)
Unallocated costs (1)
(29.4)(48.2)(69.2)(82.2)
Combined totals:
Net revenue$623.0 $606.3 $1,174.8 $1,150.2 
EBITDA from operations$131.4 $102.0 $199.0 $167.2 

(1) Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:
Three Months Ended  
December 31,
Six Months Ended  
December 31,
(Dollars in millions)2018201720182017
Impairment charges and gain/(loss) on sale of assets$0.1 $(4.2)$(2.8)$(4.2)
Stock-based compensation(7.5)(8.5)(17.5)(15.5)
Restructuring and other special items (a)
(5.9)(11.9)(19.1)(24.2)
Other (expense), net (b)
(1.4)(13.1)(7.1)(18.3)
Non-allocated corporate costs, net(14.7)(10.5)(22.7)(20.0)
Total unallocated costs$(29.4)$(48.2)$(69.2)$(82.2)
(a) Restructuring and other special items include transaction and integration costs associated primarily with the acquisitions of Catalent Indiana and Juniper.
(b) Refer to Note 8, Other Expense for details of financing changes and foreign currency translation adjustments recorded within Other (expense), net.
Reconciliation of Earnings/(Loss) from Continuing Operations to EBITDA
Provided below is a reconciliation between net earnings/(loss) and EBITDA from operations:
Three Months Ended  
December 31,
Six Months Ended  
December 31,
(Dollars in millions)2018201720182017
Net earnings/(loss)$49.0 $(21.9)$34.6 $(18.1)
Depreciation and amortization54.6 46.8 107.5 85.8 
Interest expense, net25.5 27.2 53.6 51.5 
Income tax expense2.3 49.9 3.3 48.0 
EBITDA from operations$131.4 $102.0 $199.0 $167.2 
Total Assets for Each Segment and Reconciling in Consolidated Financial Statements
The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements: 
(Dollars in millions)December 31,
2018
June 30,
2018
Assets
Softgel Technologies$1,385.0 $1,402.0 
Biologics and Specialty Drug Delivery1,793.4 1,739.7 
Oral Drug Delivery1,211.9 1,074.2 
Clinical Supply Services642.0 613.0 
Corporate and eliminations(590.7)(297.8)
Total assets$4,441.6 $4,531.1